New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.
-
Upload
shanon-bishop -
Category
Documents
-
view
221 -
download
0
Transcript of New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.
![Page 1: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/1.jpg)
New Oral Anticoagulant
R2 Patcharee SeesongsomR2 Sirada Phojai
Advisor AJ Tachawan Jiratiwanon
![Page 2: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/2.jpg)
Scope
• Overview• Introduction of NOACs• Rivaroxaban ( Xarelto )• Dabigatran ( Pradaxa )• Anesthetic implication
![Page 3: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/3.jpg)
Hemostasis
http://www.thrombosisadviser.com/en/understanding-thrombosis/haemostasis/
Primary hemostasis Secondary hemostasis
![Page 4: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/4.jpg)
![Page 5: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/5.jpg)
NEW FUNDAMENTALS IN HEMOSTASIS Physiol Rev93: 327–358, 2013doi:10.1152/physrev.00016.2011
![Page 6: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/6.jpg)
Various Phases of Coagulation
• Initiation phase• Extrinsic pathway
of coagulation.• Disrupted vasculature.• FVII, TF ( Tissue factor ).
• Amplification phase• Thrombin.
• Propagation phase
NEW FUNDAMENTALS IN HEMOSTASIS Physiol Rev93: 327–358, 2013doi:10.1152/physrev.00016.2011
![Page 7: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/7.jpg)
![Page 8: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/8.jpg)
Oral Anticoagulant Drug
• Current anticoagulants• Vitamin K antagonists : warfarin
• Novel anticoagulants• Direct Factor Xa inhibitors : rivaroxaban, apixaban
• Direct thrombin inhibitors : Ximelagatran, Melagatran, dabigatran
![Page 9: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/9.jpg)
Do you know mechanism of action of warfarin?
![Page 10: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/10.jpg)
Warfarin >> Vitamin K Antagonist
![Page 11: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/11.jpg)
Disadvantage of Warfarin
• Narrow therapeutic range.• Slow onset of action.• Slow offset of action (long duration of action,long elimination
half life) •Multiple drug and dietary interactions.•Monitoring required to maintain in therapeutic range.
Thromb Haemost 2010;103:34-39
![Page 12: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/12.jpg)
Oral Anticoagulant drug
• Novel anticoagulants
• Direct Factor Xa inhibitors : rivaroxaban ( Xarelto )
• Direct thrombin inhibitors : dabigatran ( Pradaxa )
![Page 13: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/13.jpg)
Action of Anticoagulant Drug
Rivaroxaban
Dabigatran
Rivaroxaban: An oral direct inhibitor of factor Xa,American Society of Health-System Pharma-cists, Inc. All rights reserved. 1079-2082/08/0802-1520$06.00.DOI 10.2146/ajhp070624
![Page 14: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/14.jpg)
Rivaroxaban
![Page 15: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/15.jpg)
Rivaroxaban
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting,the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2013; 118:1466-74
Direct FXa inhibitor
![Page 16: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/16.jpg)
Pharmacokinetic of Rivaroxaban
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting,the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2013; 118:1466-74
![Page 17: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/17.jpg)
Drug Interaction
Increase effect
• “ azole” antifungal (eg. ketoconazole)• HIV protease inhibitors (eg. Ritonavir)
Decrease effect
• Rifampicin, Phenytoin, carbamazepine, St. John’s wortNew Drug Review Rivaroxaban: An Oral Factor Xa Inhibitor
(Clin Ther.2013;35:427) © 2013 Published by Elsevier HS Journals, Inc.
![Page 18: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/18.jpg)
Not Recommended
• Avoid in patients with mod-severe hepatic impairment• Avoid in pregnancy women
New Drug Review Rivaroxaban: An Oral Factor Xa InhibitorClin Ther.2013;35:427.
![Page 19: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/19.jpg)
Monitoring
• Rivaroxaban prolongs the prothrombin time (PT) and this might be used as a rough estimate of an anticoagulation effect.
• A better estimate for an anticoagulant effect for the oral Factor Xa inhibitors is an anti-Xa assay.
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting,the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2013; 118:1466-74
![Page 20: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/20.jpg)
n engl j med 358;26 www.nejm.org june 26, 2008
![Page 21: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/21.jpg)
• 10-mg oral rivaroxaban 6-8 hr after wound closure
• 40 mg enoxaparin SC 12 hr before surgery, 6-8 hr after wound closure
Patients4433
Rivaroxaban
2209
Enoxaparin
2224
![Page 22: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/22.jpg)
RECORD1 clinical trials.
![Page 23: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/23.jpg)
RECORD1 clinical trials.
![Page 24: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/24.jpg)
Conclusion
• Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total hip arthroplasty, with similar rates of bleeding.• 10-mg oral of rivaroxaban VS 40-mg SC of enoxaparin.
RECORD1 clinical trials.
![Page 25: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/25.jpg)
n engl j med 358;26 www.nejm.org june 26, 2008
![Page 26: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/26.jpg)
• 10-mg oral rivaroxaban 6-8 hr after wound closure
• 40 mg enoxaparin SC 12 hr before surgery, 6-8 hr after wound closure
Patients2459
Rivaroxaban
1220
Enoxaparin
1239
![Page 27: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/27.jpg)
RECORD3 clinical trials.
![Page 28: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/28.jpg)
RECORD3 clinical trials.
![Page 29: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/29.jpg)
Conclusion
• Rivaroxaban was superior to enoxaparin for thromboprophylaxis after total knee arthroplasty, with similar rates of bleeding. • 10-mg oral of rivaroxaban VS 40-mg SC of enoxaparin.
RECORD3 clinical trials.
![Page 30: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/30.jpg)
n engl j med 365;10 nejm.org september 8, 2011
![Page 31: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/31.jpg)
• 20-mg oral rivaroxaban daily or 15 mg (CrCl 30-49 ml/min )
• Adjusted-dose warfarin (target INR 2.0-3.0)
Patients14264
Rivaroxaban
7131Warfarin
7133
![Page 32: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/32.jpg)
![Page 33: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/33.jpg)
![Page 34: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/34.jpg)
Conclusion
• In patients with AF, rivaroxaban was equal to warfarin for the prevention of stroke or systemic embolism.
• There was no significant between-group difference in the risk of major bleeding, although intracranial and fatal bleeding occurred less frequently in the rivaroxaban group.
ROCKET AF Clinical Trials.
![Page 35: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/35.jpg)
Approval
Approved by FDA, EMA ( European Medicines Agency ) & ACCP ( American College of Chest Physicians )
• VTE prophylaxis after hip or knee replacement surgery.• Stroke prevention in patients with non-valvular AF.
![Page 36: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/36.jpg)
Dosing Guidelines
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting,the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2013; 118:1466-74
![Page 37: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/37.jpg)
Dabigatran
![Page 38: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/38.jpg)
Dabigatran
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting,the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2013; 118:1466-74
Direct thrombin inhibitor
![Page 39: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/39.jpg)
Pharmacokinetic of Dabigatran
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting,the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2013; 118:1466-74
![Page 40: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/40.jpg)
Drug interaction
• Ketoconazole• Quinidine• Amiodarone• Verapamil
![Page 41: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/41.jpg)
Monitoring
• Prolong aPTT ( exclude if normal value)• Prolong thrombin time • Prolong of ECT ( ecarin clotting time ) is directly and linearly
to the plasmatic levels of dabigatran.
![Page 42: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/42.jpg)
Ecarin Clotting Time
![Page 43: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/43.jpg)
RE-LY
![Page 44: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/44.jpg)
Procedure >> 18,113 patients
Dabigatran110 mg bid
Follow up visit 14 day ,1 mo 3 m0Every 3 mo in 1 year, then 4 mo until 2 yrs
Follow up LFT montly in 1 yr then if normal performed only regular visit
![Page 45: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/45.jpg)
RE-LY clinical trails.
Stroke and systemic embolism
![Page 46: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/46.jpg)
Major bleeding
![Page 47: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/47.jpg)
Conclusion
• Patients with AF, dabigatran 110 mg oral bid VS warfarin treatment• Similar rate of stroke and systemic embolism• lower rates of major hemorrhage.
• Patients with AF, dabigatran 150 mg oral bid VS warfarin treatment• lower rate of stroke and systemic embolism• similar rates of major hemorrhage.
![Page 48: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/48.jpg)
![Page 49: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/49.jpg)
![Page 50: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/50.jpg)
![Page 51: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/51.jpg)
Conclusion
•Meta-analysis of RE-MODEL and RE-NOVATE and RE-MOBILIZE• Dabigatran etexilate is non-inferior to enoxaparin 40 mg od,
with a similar safety profile.
• No significant difference between dabigatran and enoxaparin in any of the end-points analysed• Total VTE • All cause of mortality
![Page 52: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/52.jpg)
Approval
• Stroke prevention in patients with non-valvular AF.• Approved by FDA & EMA ( European Medicines Agency ),Canada,Japan
and United states• VTE prophylaxis after hip or knee replacement surgery.• Approved in Europe and Canada • Not approved ,yet in United states
![Page 53: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/53.jpg)
Dosing Guidelines
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting,the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2013; 118:1466-74
![Page 54: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/54.jpg)
Anesthetic Implication
• Elective surgery• Emergency surgery
![Page 55: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/55.jpg)
Interruption of Target-Specific Oral Anticoagulant Therapy for Invasive
Procedures and Surgery
Oral anticoagulant therapies: Balancing the risks,Am J Health-Syst Pharm—Vol 70 May 15, 2013
![Page 56: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/56.jpg)
Recommended time intervals before and after puncture or catheter
removalTime before
puncture/cathetermanipulation or removal
Time after puncture/catheter
manipulation or removal
Rivaroxaban (for prophylaxis, 10 mg OD)
22–26 h 4–6 h
Dabigatran (for prophylaxis, 150–220 mg)
Contraindicated accordingto the manufacturer
6 h
Guideline Regional anaesthesia and antithrombotic agents: recommendations of the European Society of Anaesthesiology, Eur J Anaesthesiol 2010;27:999–1015
![Page 57: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/57.jpg)
Emergency case
![Page 58: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/58.jpg)
Managing New Oral Anticoagulants in the Perioperative and Intensive Care Unit Setting,the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2013; 118:1466-74
![Page 59: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/59.jpg)
Take Home Message
• New oral anticoagulants have approved for thromboprophylaxis after hip & knee arthroplasty and stroke prevention in non-valvular AF patient. • Rivaroxaban > Direct Fxa inhibitor. • Dabigatran > Direct thrombin inhibitor.
• No antidote available now.• If abnormal bleeding >> Supportive & symptomatic treatment.
![Page 60: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/60.jpg)
THANK YOU
![Page 61: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/61.jpg)
![Page 62: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/62.jpg)
![Page 63: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/63.jpg)
![Page 64: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/64.jpg)
![Page 65: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/65.jpg)
![Page 66: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/66.jpg)
![Page 67: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/67.jpg)
![Page 68: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/68.jpg)
![Page 69: New Oral Anticoagulant R2 Patcharee Seesongsom R2 Sirada Phojai Advisor AJ Tachawan Jiratiwanon.](https://reader036.fdocuments.in/reader036/viewer/2022062421/56649da05503460f94a8c6e6/html5/thumbnails/69.jpg)